Assessment of Dyslipidemia and its Associated Factors Among Non-Alcoholic Fatty Liver Disease Diagnosed Type 2 Diabetes Mellitus Patients in Adama Hospital Medical College: A Cross-Sectional Study
Open Access
- 6 April 2026
- journal article
- Published by SAGE Publications in Clinical Medicine Insights: Endocrinology and Diabetes
- Vol. 19
Abstract
Background: Dyslipidemia is a condition where lipid metabolism is altered, and its mechanism is closely related to non-alcoholic fatty liver disease. The alteration of lipid metabolism during non-alcoholic fatty liver disease results in disrupted uptake, oxidation, and export. Assessing dyslipidemia among non-alcoholic fatty liver disease using these lipid panel is affordable, widely available, and compatible with existing laboratory infrastructure which enables for identifying individuals at increased risk of its complications, guiding therapeutic interventions, and supporting metabolic risk management. Objective: The study aimed to assess Dyslipidemia and its associated factors among non-alcoholic fatty liver disease-diagnosed type 2 diabetes mellitus patients in Adama Hospital Medical College, 2024. Methods: An institution-based cross-sectional study design was used, and the study units were selected using a systematic random sampling technique. Sociodemographic, Behavioral, and Clinical data were collected using a structured questionnaire. Anthropometric measurements were taken by experienced nurses. Fasting venous blood was collected to test the lipid profiles and fasting blood glucose of study participants using Siemens Healthineers dimension EXL 200 chemistry analyzer. Data were assessed using STATA version 17 for correlation analysis among lipid parameters and the predictors, and P < .05 was considered statistically significant. Binary logistic regression was performed to show the statistically significant association among dyslipidemia and associated factors, and P < .05 was also considered statistically significant. Results: The overall proportion of dyslipidemia was found to be 199 (85.04%). High TG 128 (54.7%) and low HDL-C 121 (51.71%) accounts for the major abnormal lipid parameters. BMI, blood pressure, and non-alcoholic fatty liver disease showed a weak positive statistical correlation with increased LDL-C, TG, and TC and a weak negative statistical correlation with HDL-C. The odds of lack of regular exercise and non-alcoholic fatty liver disease were higher for developing dyslipidemia. Conclusions: The overall prevalence of dyslipidemia was found to be high among non-alcoholic fatty liver disease-diagnosed type 2 diabetes mellitus patients. Hypertriglyceridemia was found to be highly prevalent, followed by low HDL-C, and high LDL-C.Keywords
This publication has 29 references indexed in Scilit:
- The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatmentsNature Reviews Gastroenterology & Hepatology, 2021
- Global epidemiology of dyslipidaemiasNature Reviews Cardiology, 2021
- Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: Current Issues and Future Perspectives in Preclinical and Clinical ResearchInternational Journal of Molecular Sciences, 2020
- Dysregulated lipid metabolism links NAFLD to cardiovascular diseaseMolecular Metabolism, 2020
- Prevalence of dyslipidemia and associated risk factors among adults aged ≥35 years in northern China: a cross-sectional studyBMC Public Health, 2020
- New perspective on type 2 diabetes, dyslipidemia and non‐alcoholic fatty liver diseaseJournal of Diabetes Investigation, 2020
- Non-alcoholic fatty liver disease and associated factors among type 2 diabetic patients in southwest EthiopiaEthiopian Journal of Health Sciences, 2018
- Clinical epidemiology and disease burden of nonalcoholic fatty liver diseaseWorld Journal of Gastroenterology, 2017
- Association of trace metal elements with lipid profiles in type 2 diabetes mellitus patients: a cross sectional studyBMC Endocrine Disorders, 2017
- High prevalence of apolipoprotein B dyslipoproteinemias in non-alcoholic fatty liver disease: The lifelines cohort studyMetabolism, 2017